All
FDA Panel Unanimously Supports Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
July 15th 2020The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.
How to Find the Right Balance Between Essential Visits and Telemedicine During COVID-19
July 15th 2020Dr. Pat Basu, president and CEO of Cancer Treatment Centers of America discusses the fear surrounding cancer screenings during the COVID-19 pandemic and finding the right balance between what is an essential visit and what can be done using telemedicine.
'Easy' to Navigate Recent Flurry of Drug Approvals in NSCLC Since Most Are 'Just Another Option'
July 14th 2020Most of the data from the recent approvals of several non-small cell lung cancer drugs don’t distinguish themselves regarding efficacy or safety to what was already available before the flurry of approvals in May, according to Dr. Timothy Burns.